3 Marijuana Stocks To Add To Your Watch-List This Week

The marijuana market has been really budding over the last few years, especially with the recent monumental legislature that has been passed in North America. It seems to be a promising time for marijuana companies. Last year’s legalization of recreational pot in Canada and California, as well as the passing of the 2018 US Farm Bill which legalized hemp, may be setting the stage for more countries and/or states to “go green”.

cannabisstocks.jpg

As we see increased legalization of marijuana, whether medical or recreational, the potential to generate job opportunities and economic benefits rises. According to an Arcview Market Research and BDS Analytics report, consumer spending on legal cannabis is forecast to reach USD $11 billion this year and by 2022 it’s anticipated to surpass USD $23 billion.  Also, during that time period, the U.S. cannabis industry is expected to create over 467,000 full-time equivalent jobs, an 180% increase from 2017’s 170,000 full-time equivalent jobs. As the marijuana industry continues to grow at a rapid rate, there are several marijuana stocks to add to your watch-list.

Leafbuyer Technologies, Inc. (LBUY) announced the official launch of the leading mobile application Greenlight in Colorado and Oklahoma, further to the company’s announcement of the acquisition of Greenlight in November.  Previously, the order ahead app was only available in California and now 16 Leafbuyer dispensary clients in Colorado as well as 9 clients in Oklahoma have signed up. Through the Greenlight app, consumers can preorder their favorite cannabis products from participating dispensaries and skip the line when they go to pay and pick them up.

“In this fast-paced industry, we need to stay ahead of technology and continuously improve our offerings to drive more value to our clients,” said Kurt Rossner, CEO. “Greenlight is one more platform we have that separates us from our competition, inherently making Leafbuyer a more attractive option to dispensary clients nationwide.”

This news followed the announcement that Leafbuyer and its recently acquired mobile app, Greenlight, now integrates with Flowhub’s point of sale and compliance technology.   On both Leafbuyer.com and the Greenlight app, customers now have access to immediate, up-to-date menu information regarding product availability in dispensaries using Flowhub API and Leafbuyer platforms. Recently, the company has also signed over 50 licensed medical dispensaries within the Oklahoma market.

Tilray Inc (TLRY) is scheduled to announce Q4 earnings today March 18th after the closing bell.  The company recently announced the expansion of its global leadership team with the appointment of Andrew Pucher as Chief Corporate Development Officer. In his new role, Andrew will lead Tilray’s corporate development function, including the team that is responsible for M&A and corporate investments. He will be based in Toronto, ON, and report to CEO Brendan Kennedy.

Brenden Kennedy, CEO of said, “we’re pleased to welcome Andrew to our senior leadership team to execute strategic transactions that will further accelerate Tilray’s long-term global growth. Andrew shares our commitment to a disciplined, strategic approach in pursuing inorganic growth opportunities.

Last week, Tilray and LiveWell Canada annouced finalizing their agreement for the supply of hemp cannabidiol (CBD) to Tilray. Under the deal, LiveWell will supply Tilray with a monthly quantity of up to 300 kilograms of hemp-derived CBD isolate, or an equivalent amount of full-spectrum CBD extract. It includes an option to increase to 500 kilograms per month. Shipping will begin in Q2.

Aurora Cannabis Inc (ACB) announced last week that it has appointed Nelson Peltz as a Strategic Advisor. Mr. Peltz and Aurora will work collaboratively and strategically to explore potential partnerships that would be the optimal strategic fit for successful entry into each of Aurora’s contemplated market segments and advise on the company’s global expansion strategy.

“Nelson is a globally recognized business visionary with a strong track record of constructive engagement to generate accelerated, profitable growth and shareholder value across many industry verticals that are of great interest to us,” said Terry Booth. “Like us, Nelson also takes a long-term view of value creation to benefit all stakeholders. We look forward to working with Nelson to further extend our global cannabis industry leadership by aligning Aurora with each of the major market segments cannabis is set to impact.”

This news followed the launch of sales of cannabis oils to German pharmacies following receipt of all necessary approvals from the Canadian and German regulatory authorities. Pedanios 5/1 drops have become the first extract derived oil product compliant with the German monograph for in-pharmacy preparation.

marijuanastocks.jpg


This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between Midam Ventures LLC and Leafbuyer Technologies Inc., Midam is being paid $50,000 for a period of 30 days beginning November 1, 2018 and ending November 30, 2018. Midam has been paid an additional $50,000 and 40,000 common restricted shares of Leafbuyer Technologies, Inc. extending the contract another 30 days ending December 31, 2018. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to January 31, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to March 1, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to April 1, 2019. Midam owns 77,000 shares of Leafbuyer Technologies. Midam may buy or sell additional shares of (LBUY) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Leafbuyer Technologies Inc.

 

Advertisements

4 Marijuana Stocks That May Grow Your Portfolio

The global legal marijuana market is forecast to reach USD $146.4 billion by 2025, according to a report by Grand View Research. This growth can be contributed to the rising adoption of marijuana in several medical applications as well as the increased legalization seen around the world. The industry continues to show strength while the sentiment surrounding the stocks of the sector remains positive.

marijuanastocks.jpg

The North American legal marijuana market alone hit $12 billion last year, and analysts forecast that the market will reach $25.5 billion by 2021, according to a report by Cannabis Business Plan.  As the marijuana sector continues to generate growth, investors continue to place their bets on marijuana stocks.

Next Green Wave Holdings (NXGWF) (NGW.CN) announced that it, together with its US subsidiary Crossgate Capital US Holdings Corp. have signed a definitive agreement to acquire 100% of California-based SDC Ventures, LLC. The total value of this transaction is $20.6 million in cash, shares and performance shares to be earned over the next three years.  SDC a premium cannabis consumer products goods, manufacturing and extraction leader, with 8 leading cannabis brands, 45 CBD and THC products and a large network of retail and online sales channels including 700 Zumiez stores which compliments Next Green Wave’s current distribution opportunities.

“The SDC team shares our vision and provides expertise that is synergistic to that of Next Green Wave – to be the number 1 cannabis consumer products goods company in California,” stated Leigh Hughes, CEO. “Not only does this acquisition give us an array of premium brands associated with key world-renowned influencers to penetrate global markets, it also gives us increased distribution with revenues from sales, along with direct to consumer reach, relationships and specialty extraction methods. Having the opportunity to market through strategic brand partners to millions of validated and loyal followers is a big deal when marketing consumer products.”

This news followed the announcement of being granted Conditional Use Permits for nursery and both non-volatile and volatile extraction operations for its 3,240 ft² indoor facility by the City of Coalinga, CA as well as approval for the facility site design allowing for construction preparations to begin. This will enable Next Green Wave to accelerate its seed and seedling production program for its own yield and sales to licensed commercial growers and resellers. Furthermore, the facility will help advance innovative tissue culture research and the development of new high-quality cannabis strains using Intrexon’s (XON) Botticelli™ platform, allowing Next Green Wave to produce and sell seeds or clones that have standardized plant attributes and are pathogen and pesticide free.

Aurora Cannabis Inc (ACB) announced that it has appointed Nelson Peltz as a Strategic Advisor. Mr. Peltz and Aurora will work collaboratively and strategically to explore potential partnerships that would be the optimal strategic fit for successful entry into each of Aurora’s contemplated market segments and advise on the company’s global expansion strategy.

“Nelson is a globally recognized business visionary with a strong track record of constructive engagement to generate accelerated, profitable growth and shareholder value across many industry verticals that are of great interest to us,” said Terry Booth. “Like us, Nelson also takes a long-term view of value creation to benefit all stakeholders. We look forward to working with Nelson to further extend our global cannabis industry leadership by aligning Aurora with each of the major market segments cannabis is set to impact.”

Earlier this week, Aurora announced that it has commenced sales of cannabis oils to German pharmacies following receipt of all necessary approvals from the Canadian and German regulatory authorities. Pedanios 5/1 drops have become the first extract derived oil product compliant with the German monograph for in-pharmacy preparation. Neil Belot, Aurora’s Chief Global Business Development Officer, commented, “having established early mover advantage in selling cannabis oils in Germany, we are exceptionally positioned to extend our market leadership and accelerate the growth of our European operations”

Choom™ (CHOO.CN) (CHOOF) announced that it is entering the United States market, starting with the state of New Jersey, through its wholly owned US subsidiary, Choom Holdings USA Inc., has signed a letter of intent  to purchase an equity interest in a New Jersey based medical retail dispensary applicant in New Jersey’s upcoming Request of Applications that also intends to enter into recreational cannabis retail upon legalization, which is anticipated in 2020.

“This is our first step into the United States, and we are very excited for our partnership with this experienced group to have the Choom Brands in New Jersey.” states Chris Bogart, President & CEO.  “New Jersey is home to over 9 million people currently being served by only 12 cannabis operators in its medical program. New Jersey is an exceptional market to expand the Choom Brands.  We are very impressed with the progress they have achieved to date, and with our expertise in cannabis retail, we are confident we can help them successfully operate in the New Jersey market.”

Choom recently provided an update on its retail development strategy as an emerging consumer cannabis company that has secured one of the largest retail networks in Canada, as well as a $27 million-dollar investment from Aurora Cannabis (ACB). Choom has completed the buildouts of 17 retail locations across Western Canada and has 8 additional retail locations currently under construction.

HEXO Corp (HEXO) and Newstrike Brands Ltd. (TSX-V: HIP) annouced that they have entered into a definitive arrangement agreement under which HEXO will acquire all of Newstrike’s issued and outstanding common shares in an all-share transaction valued at approximately C$263 million.

Under the terms of the Arrangement Agreement, Newstrike shareholders will receive 0.06332 of a HEXO common share in exchange for each Newstrike common share held. The transaction has been unanimously approved by the board of directors of each of HEXO and Newstrike, and Newstrike’s board of directors recommends that its shareholders vote in favor of the Transaction.

“We’re thrilled to welcome the Newstrike team into the HEXO family.  Jay Wilgar (CEO of Newstrike) and his team have built incredible relationships, including teaming up with The Tragically Hip, and they share HEXO’s vision of bringing exceptional branded cannabis experiences to adults everywhere,” said Sebastien St-Louis, CEO and co-founder of HEXO. “With Newstrike, we’re adding talented employees and infrastructure to take HEXO to the next level on our journey to become one of the largest cannabis companies in the world. We’re extremely proud of our record of execution, and today are committing to achieving over $400 million in net revenue in 2020.”

marijuanastockstowatch.jpg


This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between Midam and Next Green Wave (NGW), Midam has been paid $150,000 from Next Green Wave (NGW) for a period from October 1, 2018 to November 8, 2018. Midam has been compensated an additional $100,000 and has extended its period of coverage to December 8, 2018. Midam has been compensated an additional $75,000 and has extended its period of coverage to January 8, 2019. Midam has been compensated an additional $50,000 and has extended its period of coverage to February 8, 2019. Midam has been compensated an additional $100,000 and has extended its period of coverage to April 12, 2019. Midam may buy or sell additional shares of (NGW) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Next Green Wave. Click here For Full Disclaimer.

4 Healthcare Stocks Gaining Momentum On Friday

Healthcare stocks are gaining momentum again this week, as sector trends in technology and new treatments are generating interest among investors. According to Modern Healthcare, “the healthcare industry has long fueled the country’s economy. Demand is expected to pick up as the population ages, people live longer, more gain insurance coverage and chronic conditions become more prevalent”.

biotechstocks.jpg

As healthcare companies work to develop new methods to improve the quality of care, whether it be technology, devices or drugs, many stocks within the sector are beginning to see higher activity in the markets.

Premier Health Group, Inc. (PHGRF) (PHGI) announced it is working with NexTech AR Solutions (NEXCF) to explore bringing augmented reality technology to its patient centric healthcare app to develop education tools for healthcare professionals and patients alike – some of which will be created and commercialized content for third parties.

“At Premier Health we pride ourselves in being at the forefront of changes in healthcare, so we are thrilled to be a part of the future of healthcare by enabling state of the art technological advancements to our patient centric telemedicine app,” said Dr. Essam Hamza, CEO. “AR has the potential to revolutionize both the access to data and the delivery of healthcare. The technology will help doctors and patients alike – doctors will have access to the latest and most relevant information about their patients while patients can use AR for self-education and improving the quality of treatment they receive.”

Premier Health recently announced the launch of a technology enabled mental health initiative to focus on providing app enabled mental health counselling for patients as well as growing its development team at Cloud Practice to support the build out of its patient centric platform and mobile app – a beta version of which will be available by end of Q2 will initially be extended to the 290 clinics in Premier Health’s ecosystem.

Premier Health other recent announcements include expansion plans to formally enter the cannabis clinic space and has been in discussions with Canadian ACMPR-Licensed Producers to develop a partnership. The company is also in the process of closing on two operating pharmacies in Metro Vancouver and entered into a partnership with a major online healthcare company in China, 360 Health enabling the Premier’s healthcare team to connect with patients virtually in China to provide second opinion services.

Trovagene, Inc. (TROV) today Noble Financial reiterated its coverage on the company to outperform and lowered the price target from $27 to $20. Trovagene announced company highlights and financial results for Q4 and full-year ended December 31, 2018 earlier this week.  The company reported quarterly losses of $(1.09) narrowing losses from $(4.61) a share the year prior, while quarterly sales of $78 thousand reflected a 57.84 percent decrease compared to last year’s sales of $185 thousand.

“We achieved a number of key milestones in 2018, including: Successful completion of the first three dose levels, without any dose-limiting toxicities, in the Phase 1b segment of our AML trial; granting of Orphan Drug Designation in Europe for the treatment of AML; presentation of preliminary clinical data from our AML trial at the American Society of Hematology (ASH) conference in December; opening of our mCRPC Phase 2 trial to full enrollment, following confirmation that the combination of onvansertib and Zytiga® is safe and well tolerated in the safety lead-in phase; submission of a new IND and protocol for our Phase 1b/2 trial in mCRC in December; strengthening of our patent portfolio around our drug candidate, onvansertib, with the issuance of two new patents; and entering into an exclusive license agreement with MIT to develop combination therapies that include anti-androgen or androgen antagonist and a Polo-like Kinase (PLK) inhibitor (onvansertib) for the treatment of cancer.” said Dr. Thomas Adams, CEO and Chairman.

Trovagene announced that two abstracts, highlighting data from its lead clinical programs of onvansertib in AML and mCRPC have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, March 29 – April 3, 2019 in Atlanta, GA.

Tonix Pharmaceuticals Holding Corp. (TNXP) announced that the European Patent Office issued European Patent No. 3246031 to the company on February 27, 2019 is expected to provide market exclusivity until April 2029.

The patent, “Method for Treating Neurodegenerative Dysfunction,” claims the use of TNX-601for treating neurocognitive dysfunction associated with corticosteroid treatment. Patents claiming the use of TNX-601, its structural analogs, and salts have previously been issued in the U.S., Canada and Europe.

“The grant of this European method of use patent is another step in expanding the patent portfolio for TNX-601,” commented Seth Lederman, M.D., President and CEO. “Tianeptine oxalate, or TNX-601, is an important product in our pipeline and is being developed not only for steroid-induced neurocognitive impairment, but also as a daytime treatment for posttraumatic stress disorder. We are conducting a non-IND human pharmacokinetic study of a proprietary tianeptine oxalate formulation and expect to have data in the second half of this year.”

Seelos Therapeutics, Inc. (SEEL) announced that it has acquired an exclusive license to intellectual property owned by The Regents of the University of California pertaining to a technology created by researchers at the University of California, Los Angeles (UCLA). The technology relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (α-synuclein).

Seelos intends to study this initial approach in Parkinson’s disease (PD) and will further evaluate the potential clinical approach in other central nervous system disorders. This new program will be dubbed SLS-007. Pre-clinical data provides supportive evidence to slow progression – an early sign of disease-modifying potential in PD. Under the terms of the agreement, Seelos has made an upfront payment of $100,000 and will issue future payment in the form of royalties, contingent upon commercialization.

“Despite current available treatments for PD, including levodopa and deep brain stimulation, long-term outcomes for patients remain poor,” said Tim Whitaker, MD, Head of R&D. “With no disease-modifying treatments, and long-term use of established dopaminergic therapies resulting in both adverse events and side effects, significant need remains to develop not only a better means of restoring striatal dopamine but a safe and effective treatment that slows progression of the disease in patients with PD. If we are successful in our planned pre-clinical and future clinical studies, SLS-007 may prove to be such a treatment.”

healthcarestocks.jpg


This blog is an affiliate of MIDAM VENTURES LLC. Pursuant to an agreement between Midam and Premier Health Group Inc., Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam owns zero shares of Premier Health Group Inc., which Midam purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that Midam holds currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.

3 Marijuana Stocks To Watch This Week

The marijuana industry continues to show strength while the sentiment surrounding marijuana stocks remains very positive this year, possibly demonstrating even more signs of growth than seen in previous years. The global legal marijuana market is forecast to reach USD $146.4 billion by 2025, according to a report by Grand View Research. This growth can be contributed to the rising adoption of marijuana in several medical applications as well as the increased legalization seen around the world.

cannabisstocks.jpg

As marijuana continues to generate a more favorable opinion among the masses, investors looking for potential opportunities may benefit from keeping tabs on this rapidly growing industry.  For those that may be weary of a pure-play positions in marijuana stocks, there are companies that hold positions in traditional industries, while also working to expand a portion of their business to include the budding marijuana industry.

Premier Health Group, Inc. (PHGRF) (PHGI) announced its expansion plans to formally enter the cannabis clinic space and has been in discussions with Canadian ACMPR-Licensed Producers in order to partner with a, or multiple, Licensed Producers.

“We are currently working on a partnership model to hard code the decision-making process into the Electronic Medical Records (EMR),” said Dr. Essam Hamza, CEO. “There has been a critical gap between the patient’s need for medical cannabis and the doctor’s knowledge and comfort level in prescribing it. At Premier we understand the frustration felt from both the patient and the doctor and are integrating what we think is a revolutionary process. This new tool will allow us to provide a much-needed service to the 287 clinics and almost 3 million patients in our ecosystem.”

Most recently, Premier Health announced the launch of a technology enabled mental health initiative which will focus on providing app enabled mental health counselling for patients in urban and remote populations as well as growing its full-time development team at Cloud Practice by hiring 3 Web Software Developers and 1 User Interface/User Experience Designer to support the build out of its patient centric platform and mobile app – a beta version of which will be available by end of Q2.

The company is also in the process of closing on two operating pharmacies in Metro Vancouver and has entered into a strategic partnership with a major online healthcare company in China, 360 Health enabling the Premier’s healthcare team to connect with patients virtually in China to provide second opinion services.

Arcadia Biosciences (RKDA) announced that it has been granted an Industrial Hemp Pilot Program License by Hawaii’s Department of Agriculture. The license allows for the cultivation of industrial hemp in Hawaii for the purposes of agricultural and academic research. Hemp and hemp products produced under the program may be commercially sold. With this license, Hawaii becomes the first state where Arcadia Specialty Genomics will commence its research and cultivation of hemp, planting on ten acres of recently-leased land next month.

“With the explosive market growth projected in the industrial hemp and derivative markets, growers will need the very best hemp strains to meet demand, minimize waste, and ensure consistent quality. As the only company working in the cannabis industry with proven track record of improving plants and commercializing food ingredients from agricultural products using non-GM techniques, we’re ideally positioned to help hemp growers and end-users benefit from better hemp strains,” said Matt Plavan President of Arcadia Specialty Genomics.

This news followed last week’s launch of the company’s new division Arcadia Specialty Genomics, a first-of-its-kind strategic business unit to the optimization and standardization of cannabis plant content, quality, climate resiliency and yield to solely focus on the hemp market.

Medigus Ltd. (MDGS) announced that it has entered into a binding memorandum of understanding with Linkury Ltd., a wholly owned subsidiary of Algomizer Ltd., a leading company in the field of online advertising, to establish an e-commerce program for cannabidiol (CBD) products.

The agreement entails the two companies will invest in setting up an Internet platform, where Internet marketing, the establishment of an e-commerce platform and video sites will be carried out by Linkury, and the manufacturing, operation, and regulation related to the CBD products will be carried out by Meidgus. The companies will jointly invest up to $500,000 in the venture for infrastructure and marketing and will own it in equal parts. Furthermore, the two companies will explore entering into a definitive agreement and the formation of an international advertisement company, which will carry out the joint venture.

This is Medigus’ first investment in industry, following the announcement in mid-February of its intent to enter the CBD and medical cannabis markets. This venture is in accordance with the strategy of the company’s management and board of directors to bring value to the company and its shareholders, according to the company.

marijuanastocks.jpg


This blog is an affiliate of MIDAM VENTURES LLC. Pursuant to an agreement between Midam and Premier Health Group Inc., Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam owns zero shares of Premier Health Group Inc., which Midam purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that Midam holds currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.

3 Healthcare Stocks That May Grow Your Portfolio

The global medical technology industry’s market size is currently around USD $400 billion and is forecast to hit USD $495 billion over the next three years, according to a PwC report. The term “medical technology” covers a broad range of products, from devices to drugs as well as software. Technological advancements in the industry assist to save lives by improving the accuracy of diagnoses, improving treatments, and evolving medical care.

stockstobuy.jpg

These fresh technological developments continue to boost excitement within the market. Demand for healthcare is forecast to grow as the aging population increases and a rise in prevalence of chronic diseases.  From data-based approaches to potential blockbuster drug candidates, advancements in healthcare may catalyze opportunities for investors looking to healthcare stocks.

Premier Health Group, Inc. (PHGRF) (PHGI) announced it is growing its development team at Cloud Practice Inc. to support its focus on digitizing healthcare by hiring four new full-time employees, three Web Software Developers and one User Interface/User Experience Designer to support the build out of its patient centric platform and mobile app – a beta version of which will be available by end of Q2, according to the company. The new patient portal will provide Cloud Practice clients with additional services which will be provided via a SaaS (software-as-a-service) model, allowing for new recurring revenues that are scalable and will initially be extended to the 290 clinics in Premier Health’s ecosystem.

“The future of healthcare is digitally driven and this strategic investment in growing Cloud Practice’s team will enable us to fast-track the build out our app – a much-needed technology innovation in healthcare,” said Dr. Essam Hamza, CEO. “Our goal is to tackle the accessibility bottlenecks by putting the power in the hands of patients. Not only will our app enable patients’ access to their health care providers, but also allow for cohesive patient care by coordinating and connecting all members of their health care team.”

Premier Health recently announced expansion plans to formally enter the cannabis clinic space and has been in discussions with Canadian ACMPR-Licensed Producers in order to partner with a, or multiple, Licensed Producers. The company is also in the process of closing on two operating pharmacies in Metro Vancouver, with a combined revenue of approximately $6 million (FY 2018) and anticipates the acquisition to close in or about Q2 2019 and entered into a strategic partnership with a major online healthcare company in China, 360 Health enabling the Premier’s healthcare team to connect with patients virtually in China to provide second opinion services.

Biocept Inc. (BIOC) announced that it will collaborate with Providence St. Joseph Health, Southern California, and its wholly owned affiliates Providence Saint John’s Health Center and the John Wayne Cancer Institute, to conduct a study to validate the use of cerebrospinal fluid (CSF) as a specimen type with Biocept’s Target Selector™ liquid biopsy platform.

Biocept’s liquid biopsy platform will be used to evaluate the CSF of patients diagnosed with certain types of cancer, such as breast, lung and melanoma, as well as other malignancies to determine if leptomeningeal metastases have occurred. The results from Biocept’s liquid biopsy testing will be compared to standard methods for confirming the diagnosis of leptomeningeal metastases.

“We are very pleased to collaborate with Dr. Kesari and Providence St. Joseph Health in this study designed to further validate the clinical utility of our Target Selector™ platform using the CSF of patients with cancer,” said Michael W. Nall, President and CEO. “Among the significant advantages of our liquid biopsy technology is its versatility, which enables its application in a variety of clinical situations and for use with multiple types of biofluids. Results of this study could open new market opportunities for Biocept.”

Midatech Pharma (MTP) confirmed that further to its announcement made on January 29, 2019, the strategic investment by China Medical Systems Holdings Limited group (CMS) and A&B license agreement is now formally active. The investment by CMS and A&B, comprised an £8m subscription in Midatech, for a total of 207,792,206 Ordinary Shares at a price of 3.85 pence per share.

CMS has rights to develop and commercialize the Midatech’s pipeline of products in Greater China and certain South East Asian.  Subject to certain milestones being achieved, Midatech will be entitled to receive regulatory and sales-based milestone payments as well as royalty payments. The collaboration provides the company with access to the Chinese market and substantial investment and funds for Midatech’s current key programs, as well as additional CMS funded opportunities for the Company’s technology platforms Q-Sphera, MidaSolve, and MidaCore.

Dr Craig Cook, CEO, said: “We are delighted to finalise the licence agreement with China Medical Systems, a leading Hong Kong based Chinese pharmaceutical company. This is a key collaboration for Midatech that provides a strong endorsement of our technologies and pipeline whilst establishing a solid foundation for a successful and ambitious long-term partnership. The agreement will enable development of current and new products and extend our reach to the important markets of China and South East Asia. We look forward to developing this collaboration with CMS.”

biotechstocks.jpg


This blog is an affiliate of MIDAM VENTURES LLC. Pursuant to an agreement between Midam and Premier Health Group Inc., Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam owns zero shares of Premier Health Group Inc., which Midam purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that Midam holds currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.

 

3 Healthcare Stocks Gaining Investor Attention

Healthcare stocks are gaining momentum again this week, as sector trends in technology and new treatments for diseases are generating increased interest among investors. According to Modern Healthcare, “the healthcare industry has long fueled the country’s economy. Demand is expected to pick up as the population ages, people live longer, more gain insurance coverage and chronic conditions become more prevalent”.

healthcarestocks.jpg

As healthcare companies work to develop new methods to improve the quality of care that can be provided, whether it be technology, devices or drugs, the industry, in its entirety, is expected to unite to meet the demands and needs of consumers seeking quality healthcare. With the growing global demand for healthcare, stocks within the sector are starting to see higher activity in the markets.

Premier Health Group, Inc. (PHGRF) (PHGI) recently provided a corporate update.  The company announced as a part of its expansion plans, it is formally entering the cannabis clinic space and has been in discussions with Canadian ACMPR-Licensed Producers in order to partner with a, or multiple, Licensed Producers. Premier Health’s recent acquisition of Cloud Practice, a medical software company, has provided the company with an underlying platform to help empower and streamline patient-doctor interaction.

“We are currently working on a partnership model to hard code the decision-making process into the Electronic Medical Records (EMR),” said Dr. Essam Hamza, CEO. “There has been a critical gap between the patient’s need for medical cannabis and the doctor’s knowledge and comfort level in prescribing it. At Premier we understand the frustration felt from both the patient and the doctor and are integrating what we think is a revolutionary process. This new tool will allow us to provide a much-needed service to the 287 clinics and almost 3 million patients in our ecosystem.”

Premier Health is also in the process of closing on two operating pharmacies in Metro Vancouver, with a combined revenue of approximately $6 million (FY 2018) and anticipates the acquisition to close in or about Q2 2019. The company also recently announced a partnership with a major online healthcare company in China, 360 Health enabling the Premier’s healthcare team to connect with patients virtually in China to provide second opinion services.

ARCA biopharma, Inc. (ABIO) announced reaching an agreement with the U.S. FDA regarding a Special Protocol Assessment (SPA) on the design of Phase 3 clinical trial, PRECISION-AF, to assess the safety and efficacy of GencaroTM as a genetically-targeted treatment for atrial fibrillation (AF) in patients with a specific type of heart failure (HF) which currently has no FDA approved drug therapies.

“Consistent with our mission to develop precision therapies on a pharmacogenetic platform, this SPA agreement with the FDA provides a clearly defined regulatory pathway for the Phase 3 development of Gencaro in a genotype-specific heart failure population that currently has no FDA approved drug therapy,” said Michael R. Bristow, MD, PhD, CEO. “If the previous foundational therapeutic observations in the GENETIC-AF and BEST trials are confirmed in PRECISION-AF, we believe Gencaro could potentially provide a new standard of treatment for AF prevention for the estimated 2.5 million HFmrEF patients in the major markets in U.S., Europe and Japan.”

If the PRECISION-AF trial is successful and Gencaro gains regulatory approval, it has the potential to be the first genetically-targeted cardiovascular therapy, the only drug therapy indicated in HF patients with mid-range ejection fraction (HFmrEF) and the only drug therapy for AF approved against an active comparator.

Clearside Biomedical, Inc. (CLSD) announced that it received notification from the U.S. FDA that the Agency has accepted for review the New Drug Application (NDA) for XIPERE for Suprachoroidal Injection for the treatment of macular edema associated with uveitis. The FDA has determined that the application is sufficiently complete to permit a substantive review.

The NDA filing is supported by data from the Phase 3, PEACHTREE clinical trial that demonstrated significant and clinically meaningful improvement in vision for patients with macular edema associated with non-infectious uveitis, and that improvement was achieved across all anatomical locations of uveitis. Also, in patients with active inflammation at baseline, resolution was achieved in more than two-thirds of those treated with XIPERE across three commonly used measures of inflammation: vitreous haze, anterior chamber cells and anterior chamber flare.

“We are delighted with this positive news on our XIPERE NDA. If XIPERE is approved, Clearside will have the first therapy indicated for patients suffering from macular edema associated with uveitis,” said Daniel H. White, President and CEO. “Macular edema is the leading cause of vision loss, and even blindness, in uveitis patients, and we are now one step closer to treating this underserved patient population. Over the last several months, our team has worked diligently to reach this milestone and we are now preparing to launch the product if approved.”

biotechstocks.jpg


This blog is an affiliate of MIDAM VENTURES LLC. Pursuant to an agreement between Midam and Premier Health Group Inc., Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam owns zero shares of Premier Health Group Inc., which Midam purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that Midam holds currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.

3 Healthcare Stocks Setting The Pace On Wednesday

Over the next several years, large transformations are expected to disrupt the healthcare industry.  The market research firm, Frost & Sullivan, predicts that this year will be the year for technology such as big data analytics, artificial intelligence, and mHealth to drive the industry to more sustainable business models.

healthcarestocks.jpg

Sandeep Sinha of Frost & Sullivan stated, “Our interactive workshop is designed to help managers and CEOs understand key issues affecting the healthcare industry globally. Advances in areas ranging from cancer immunotherapy products to blood testing, as well as the convergence of cutting-edge technology such as artificial intelligence and blockchain will help shape the healthcare industry into a much-anticipated, value-based care paradigm”.

Healthcare companies working to develop novel approaches to traditional care offerings may catalyze opportunities to investors looking to healthcare stocks.

Premier Health Group, Inc. (PHGRF) (PHGI) annouced that it has acquired all of the outstanding securities of Cloud Practice Inc., a medical software company. The combined Premier and Cloud Practice ecosystem consists of over 3,000,000 patients and provides the company with an underlying platform to help empower and streamline patient-doctor interaction.

“We are very excited to have completed this acquisition and to have the experienced team at Cloud Practice join the team at Premier Health. With this acquisition, we now have a medical software company with national reach. Thus, enabling us to build on our patient-centric technology platform that will integrate telemedicine, online booking and other premium services with our electronic medical records (EMR) system,” said Dr. Essam Hamza, CEO.

Premier Health most recently announced it is formally entering the cannabis clinic space and has been in discussions with Canadian ACMPR-Licensed Producers in order to partner with a, or multiple, Licensed Producers and expects to provide additional updates later this quarter. The company is also moving forward with a binding LOI to acquire two Vancouver-based pharmacies and anticipates the acquisition to close in or about Q2 2019. Premier has also entered into a strategic partnership with China’s 360 Health, whereby Premier will be provide second opinion services by connecting 360 Health’s patients in China with doctors in Canada both remotely and in person.

ReWalk Robotics, Ltd. (RWLK) develops, manufactures and markets wearable robotic exoskeletons for lower limb disabilities as a result of spinal cord injury or stroke. The company announced today that Cigna Corporation (CI)   has revised its previous non-coverage policy regarding coverage of exoskeleton medical devices and will now review submissions on a case-by-case basis to consider providing coverage based on medical criteria. This policy revision is the first of its kind by a major private insurer for individuals eligible to use exoskeleton devices.

“This is a major milestone for healthcare beneficiaries in the United States,” said CEO Larry Jasinski. “Cigna is leading by example with its understanding of emerging technologies, a focus on improving the overall health and well-being of beneficiaries, and most of all, in the development of progressive policies. This new policy is expected to have an immediate impact on the lives of qualified beneficiaries who will now have access to life changing medical devices.”

ReWalk recently reported Q4 financial results in which highlights include: Total revenue for the quarter was $1.6 million compared to $1.5 million in the prior year, sales in Europe grew to $1.24 million driven primarily by the German national coverage code that was issued in June 2018 and 2018 gross margin improved to 43.2%, from 40.0% in 2017.

Geron Corporation (GERN) coverage was initiated today by BTIG Research with a Buy rating and new price target of $4.  Geron recently announced several key leadership decisions over the past month as the company works to restructure their in-house development team to further support its plans to initiate a Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes by mid-year 2019.

The company announced the appointment of a new chief medical officer Dr. Aleksandra Rizo. Israel Gutierrez, M.D. as Vice President, Pharmacovigilance and Drug Safety and Andrew J. Grethlein, Ph.D., as Executive Vice President and Chief Operating Officer.

“As we transition to a late-stage development company, we are very pleased to welcome Dr. Aleksandra Rizo to Geron as Chief Medical Officer,” said John A. Scarlett, M.D., Chairman and CEO. “With Aleksandra’s prior experience as the clinical lead for the imetelstat program for more than three years at Janssen, as well as her wealth of leadership experience with other hematology-oncology development projects at both Janssen and Celgene, we believe she is uniquely suited to build and lead our clinical development team.”

biotechstocks.jpg


This blog is an affiliate of MIDAM VENTURES LLC. Pursuant to an agreement between Midam and Premier Health Group Inc., Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam owns zero shares of Premier Health Group Inc., which Midam purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that Midam holds currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.